List of Excipients in Branded Drug METHYLIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
SHIONOGI INC	METHYLIN	methylphenidate hydrochloride	59630-750	ANHYDROUS CITRIC ACID
SHIONOGI INC	METHYLIN	methylphenidate hydrochloride	59630-750	GLYCERIN
SHIONOGI INC	METHYLIN	methylphenidate hydrochloride	59630-750	POLYETHYLENE GLYCOL 1450
SHIONOGI INC	METHYLIN	methylphenidate hydrochloride	59630-750	WATER
SHIONOGI INC	METHYLIN	methylphenidate hydrochloride	59630-760	ASPARTAME
SHIONOGI INC	METHYLIN	methylphenidate hydrochloride	59630-760	CELLULOSE, MICROCRYSTALLINE

Methylin Excipient Strategy and Commercial Opportunities

Last updated: August 12, 2026

Methylin is an immediate-release methylphenidate hydrochloride product marketed in tablet, chewable-tablet, and oral-solution forms. Its commercial opportunity is not based on novel active-ingredient protection. Methylphenidate has been marketed for decades, and competition is primarily driven by dosage-form convenience, pediatric acceptability, supply reliability, pricing, and regulatory execution. Excipient selection can support differentiated generic, authorized-generic, 505(b)(2), and specialty pediatric products, but excipients cannot materially change the product's controlled-substance obligations or establish broad exclusivity by themselves.

What is Methylin and which dosage forms use it?

Methylin contains methylphenidate hydrochloride, a central nervous system stimulant indicated for attention-deficit/hyperactivity disorder and narcolepsy. The immediate-release product is administered multiple times daily, creating opportunities for improved palatability, dosing flexibility, and adherence.

Product form	Typical strengths	Primary commercial role	Excipient-sensitive attributes
Immediate-release tablet	5 mg, 10 mg, 20 mg	Low-cost oral solid	Swallowability, tablet robustness, disintegration
Chewable tablet	2.5 mg, 5 mg, 10 mg	Pediatric dosing	Taste, mouthfeel, dose uniformity
Oral solution	5 mg/5 mL and 10 mg/5 mL presentations	Pediatric and flexible dosing	Palatability, preservative system, sugar content, chemical stability
Extended-release methylphenidate products	Multiple product-specific strengths	Once-daily treatment	Release-control technology, food effect, abuse-deterrence considerations

Methylin immediate-release dosage forms are distinct from extended-release methylphenidate products such as Concerta, Quillivant XR, Ritalin LA, and other modified-release formulations. Their regulatory and patent profiles should not be conflated.

What excipients are used in Methylin products?

The excipient composition depends on the dosage form and manufacturer. Public labeling identifies conventional pharmaceutical excipients rather than a proprietary delivery platform.

Methylin tablets and chewable tablets

Methylin tablet and chewable-tablet formulations use conventional excipients associated with direct-compression or compressed-tablet manufacturing. Label-listed components include combinations of lactose monohydrate, microcrystalline cellulose, magnesium stearate, stearic acid, talc, and sweetening or flavoring agents, depending on the strength and dosage form.[1]

The commercial function of these ingredients is conventional:

• Lactose monohydrate provides bulk and compressibility.
• Microcrystalline cellulose supports tablet hardness and disintegration.
• Magnesium stearate reduces punch and die friction.
• Stearic acid may support lubrication and tablet structure.
• Talc can improve manufacturing flow and reduce sticking.
• Saccharin sodium and flavoring agents support chewable-tablet acceptability.

The most important excipient risk in chewable Methylin is not manufacturing cost. It is taste masking. Methylphenidate hydrochloride has an active pharmaceutical ingredient taste that can limit pediatric acceptance. A formulation that passes dissolution and content-uniformity testing but produces poor taste may lose commercial value in the pediatric market.

Methylin oral solution

Methylin oral solution uses a liquid vehicle and a sweetener-flavor-preservative system. Public labeling identifies ingredients such as sucrose, glycerin, sorbitol, sodium saccharin, flavoring, citric acid, sodium citrate, methylparaben, and propylparaben, subject to product-specific labeling.[2]

Each component has a defined commercial purpose:

Excipient function	Common formulation objective
Sucrose	Sweetness and viscosity
Sorbitol	Sweetness, body, and partial sugar reduction
Glycerin	Humectancy, viscosity, and mouthfeel
Sodium saccharin	High-intensity sweetness
Citric acid and sodium citrate	pH control and flavor balance
Methylparaben and propylparaben	Microbial preservation
Flavor system	Reduction of bitterness and metallic notes

Liquid formulations create additional development risks. These include preservative effectiveness, microbial control, sedimentation or crystallization, pH drift, container-closure compatibility, dosing-device accuracy, and chemical stability. Sugar-containing products also face limitations in diabetic populations and may create dental-health concerns.

Which excipient strategy offers the strongest commercial opportunity?

The strongest opportunity is a pediatric acceptability platform that improves taste while preserving immediate-release pharmacokinetics and a simple regulatory pathway.

1. Sugar-reduced or sugar-free oral solution

A sugar-reduced formulation could target parents, clinicians, hospitals, and pharmacies seeking lower sugar exposure. The formulation would need to replace or reduce sucrose without creating excessive aftertaste, gastrointestinal intolerance, or viscosity changes.

Potential excipient approaches include:

• Polyol-based systems using sorbitol, xylitol, or glycerin.
• High-intensity sweetener combinations.
• Flavor-modulation systems that reduce bitterness before sweetness is added.
• Buffer adjustment to improve flavor perception.
• Lower-viscosity formulations optimized for oral syringes.

The main risks are osmotic gastrointestinal effects, preservative compatibility, and differences in dosing behavior. A sugar-free claim can provide marketing differentiation, but it is unlikely to support strong patent protection unless paired with a technically distinctive composition or stability profile.

2. Improved-taste chewable tablet

A chewable product can support younger patients who cannot swallow tablets. The formulation target is not simply sweetness. It must manage API bitterness, powdery mouthfeel, residual aftertaste, and tablet fracture.

Possible strategies include:

• Polymer or lipid taste-masking coatings.
• Ion-exchange resin complexes.
• Multi-particulate granules compressed into a chewable matrix.
• Flavor combinations designed for early and late taste phases.
• Porous or fast-disintegrating structures that reduce residence time in the mouth.

A taste-masked formulation may have a stronger intellectual-property position than a conventional excipient substitution. However, it must demonstrate acceptable drug release after chewing. Excessive coating or complexation can delay dissolution and create bioequivalence problems.

3. Smaller-volume concentrated liquid

A 10 mg/5 mL solution already provides twice the concentration of a 5 mg/5 mL product. A further concentration strategy could reduce administration volume, shipping cost, and caregiver burden. The commercial benefit is greatest for adolescents and adults who still require liquid dosing because of swallowing limitations.

The principal development constraints are dose-measurement accuracy, palatability, solubility, preservative concentration, and the risk of medication errors. Concentrated Schedule II liquids require clear labeling and a calibrated oral syringe. A higher concentration can increase the consequence of dosing mistakes, which may weaken the commercial case unless the delivery device is tightly integrated with the product.

4. Excipient platform for sensitive populations

Methylin products may be differentiated through removal or reduction of excipients that concern specific patient groups:

• Dye-free formulations.
• Allergen-conscious formulations.
• Reduced-sugar formulations.
• Gluten-free formulations where supported by manufacturing controls.
• Lower-sodium formulations.
• Products without parabens, where an alternative preservation system is validated.

These attributes can improve formulary positioning and pharmacy substitution strategy. They usually provide limited standalone patent value. Their commercial value depends on clear labeling, reliable supply, and payer or institutional purchasing preferences.

What formulation patents could protect a Methylin opportunity?

Patent value would depend on the technical relationship between the excipient system and the product's performance. A patent directed only to replacing one sweetener with another is vulnerable to design-around and may have limited enforceability. Stronger claims could cover a defined composition linked to measurable technical results.

Potential claim categories

Claim category	Potential protected subject matter	Relative strength
Composition	Defined API, excipient, buffer, flavor, and preservative ranges	Moderate if technically narrow and non-obvious
Taste masking	Coated particles, resin complex, lipid barrier, or multiparticulate system	Moderate to strong if performance is demonstrated
Stability	Composition that controls degradation or preservative loss	Moderate if linked to unexpected stability
Device-product combination	Oral syringe, bottle, adapter, and concentrated solution	Moderate, with design-around risk
Manufacturing process	Granulation, coating, drying, or blending sequence	Moderate if process is difficult to replicate
Method of use	Administration to a defined pediatric population or dosing condition	Usually limited for immediate-release methylphenidate
Packaging	Light-resistant, child-resistant, or dose-controlled packaging	Usually weak unless technically integrated

Composition-of-matter protection for methylphenidate itself is unavailable as a practical commercial strategy because the active ingredient is longstanding. The defensible estate would instead focus on formulation, process, packaging, device, or regulatory exclusivity.

When does Methylin lose exclusivity?

Methylin does not have the exclusivity profile of a newly approved chemical entity or biologic. Methylphenidate hydrochloride is an established small-molecule active ingredient, and immediate-release products compete through abbreviated applications, product availability, and dosage-form differentiation.

The relevant exclusivity categories are:

Exclusivity category	Relevance to Methylin
New chemical entity exclusivity	Not applicable to longstanding methylphenidate
Orphan-drug exclusivity	Not applicable to the general ADHD indication
Pediatric exclusivity	Possible only if separately awarded for qualifying FDA studies
New formulation exclusivity	Potentially relevant to a new approved dosage form
Three-year clinical-investigation exclusivity	Possible for an application supported by qualifying new clinical investigations
Five-year NCE exclusivity	Not applicable to methylphenidate hydrochloride
Patent exclusivity	Depends on formulation, process, device, or method claims
Controlled-substance restrictions	Continue independently of patent status

The commercial question is therefore not when the active ingredient loses exclusivity. It is whether a specific formulation or delivery system has enforceable patent or regulatory protection and whether a competing product can obtain FDA approval without infringing it.

What is the Orange Book status of Methylin?

The FDA Orange Book identifies approved drug products, therapeutic-equivalence evaluations, patent information submitted by application holders, and applicable exclusivity data.[3] Methylin's Orange Book relevance is product-specific because tablet, chewable-tablet, and oral-solution presentations may have different application numbers, manufacturers, and regulatory histories.

For an immediate-release Methylin strategy, the key Orange Book issues are:

1. Whether the reference listed drug remains active for the intended dosage form and strength.
2. Whether the proposed product can use an ANDA pathway.
3. Whether any listed patents cover the reference product's formulation, method of use, or delivery system.
4. Whether the reference product has an active exclusivity block.
5. Whether the proposed product must submit Paragraph IV certifications.

A generic applicant should not assume that a brand name appearing in historical labeling has a current, active commercial reference product. FDA approval status, marketing status, and Orange Book reference-product designation can change over time.

Are Paragraph IV challenges likely for Methylin?

Paragraph IV risk is generally lower for conventional immediate-release methylphenidate than for extended-release products. A generic applicant may be able to rely on an established active ingredient and a conventional dosage form, subject to bioequivalence, labeling, controlled-substance, and manufacturing requirements.

Paragraph IV exposure increases when the proposed product includes:

• A novel taste-masking system.
• A concentrated liquid with a new excipient architecture.
• A device-linked dosing system.
• A modified-release profile.
• A formulation patent listed for the reference product.
• A method-of-use claim tied to a specific regimen.

The strategic distinction is important. A conventional Methylin-equivalent product may face price competition with limited patent litigation. A differentiated product may generate greater margin but also creates its own patent risk if it relies on proprietary excipients, coating technology, or device integration.

What FDA regulatory pathway is appropriate for a Methylin formulation?

ANDA pathway

An ANDA is generally the most efficient route for a conventional immediate-release tablet, chewable tablet, or oral solution that can demonstrate pharmaceutical equivalence and bioequivalence to an appropriate reference product.[4]

The principal technical requirements include:

• Same active ingredient.
• Same dosage form and strength.
• Equivalent conditions of use.
• Pharmaceutical equivalence.
• Bioequivalence.
• Comparable labeling, subject to permitted differences.
• Current good manufacturing practice compliance.

Excipient differences are possible, but they must not affect safety, efficacy, manufacturability, or bioequivalence. Certain excipient changes may require additional justification, especially for pediatric products or products administered in larger liquid volumes.

505(b)(2) pathway

A 505(b)(2) application may be appropriate for a materially differentiated product that cannot rely entirely on an existing product's safety and efficacy findings. Examples include:

• A new concentration.
• A new delivery device.
• A new dosage form.
• A clinically meaningful formulation change.
• A product with a new route or dosing regimen.

This pathway may support formulation and regulatory exclusivity, but it generally requires a stronger clinical and pharmacology package than a conventional ANDA.

How strong is the Methylin patent estate?

The patent estate for conventional immediate-release Methylin is likely weaker than the estates surrounding extended-release methylphenidate products. The active ingredient is old, and standard excipients such as lactose, cellulose, glycerin, sorbitol, buffers, and parabens are widely used.

Patent strength would be higher for a product that combines:

• A difficult-to-reproduce taste-masking technology.
• A defined particle or coating structure.
• Demonstrated stability improvement.
• A specialized oral dosing device.
• A manufacturing process that produces a critical product attribute.
• Clinical evidence tied to the formulation.

A practical freedom-to-operate review should separate patents covering the reference product from patents covering the proposed product's own formulation. A design-around may avoid reference-product claims while creating new claims that third parties could assert against the follow-on product.

Which companies compete with Methylin?

Methylin competes within a broad methylphenidate market rather than against a single product. Relevant competitors include:

Product category	Examples	Competitive pressure
Immediate-release tablets	Generic methylphenidate tablets, Ritalin-type products	High price pressure
Chewable methylphenidate	Methylin chewable and competing pediatric products	Moderate, driven by taste and availability
Oral solution	Methylin oral solution and liquid methylphenidate products	Moderate, driven by dosing convenience
Extended-release tablets	Concerta and generic equivalents	Strong substitution for once-daily therapy
Extended-release liquids	Quillivant XR and similar products	Strong pediatric convenience competition
Capsules and multiparticulates	Ritalin LA and other modified-release products	Differentiated adherence and duration
Non-methylphenidate stimulants	Amphetamine products	Therapeutic substitution
Nonstimulants	Atomoxetine, viloxazine, guanfacine, clonidine	Alternative treatment classes

A Methylin-based commercial program should therefore avoid competing only on tablet price. The more defensible segments are pediatric taste, flexible dosing, sugar reduction, device accuracy, and reliable supply.

What manufacturing and IP barriers affect Methylin opportunities?

Manufacturing barriers are moderate for standard tablets and higher for differentiated liquids or taste-masked chewables.

Immediate-release tablets

The process is relatively conventional. Key controls include blend uniformity, tablet weight, hardness, friability, disintegration, dissolution, and content uniformity. The primary barrier is commercial scale and controlled-substance compliance rather than unusual technology.

Chewable tablets

The process must control flavor uniformity, particle segregation, compression behavior, friability, and sensory performance. Taste-masking coatings can add equipment requirements, yield loss, and dissolution risk.

Oral solutions

Liquid manufacturing requires validated mixing, pH control, preservative effectiveness, microbial limits, filling accuracy, and container-closure compatibility. Oral syringes and adapters introduce combination-product quality requirements and can increase packaging complexity.

Methylphenidate is a controlled substance under U.S. law. Quota management, security, recordkeeping, inventory controls, and distribution requirements can restrict supply-chain flexibility and increase working-capital exposure.[5]

What commercial opportunities exist for Methylin?

The most viable opportunities are:

1. A sugar-free or reduced-sugar oral solution with strong pediatric taste performance.
2. A chewable tablet with validated bitterness reduction and improved mouthfeel.
3. A concentrated liquid packaged with a dose-specific oral syringe.
4. A dye-free or excipient-reduced product for institutional and caregiver preferences.
5. A supply-reliable authorized generic or private-label product.
6. A 505(b)(2) product combining a differentiated liquid with a dosing device.
7. A formulation platform that can be extended to other pediatric controlled substances.

Revenue exposure should be modeled against generic erosion, product availability, pharmacy substitution, payer reimbursement, Schedule II distribution constraints, and the extent to which the product can command a premium. A conventional tablet is likely to produce volume with limited margin. A differentiated liquid or chewable can support higher gross margin if the taste and dosing advantages are clinically and commercially visible.

Key Takeaways

• Methylin is an immediate-release methylphenidate hydrochloride product available in tablet, chewable-tablet, and oral-solution forms.
• Excipients are the main route to product differentiation because the active ingredient is longstanding.
• Taste masking, sugar reduction, concentrated dosing, and device integration offer the strongest commercial opportunities.
• Conventional excipient substitutions usually provide weak patent protection.
• Stronger patents would link a defined excipient system to taste, stability, dissolution, or manufacturing performance.
• An ANDA is the likely route for a conventional equivalent product; a 505(b)(2) application may fit a materially differentiated formulation.
• Immediate-release products face substantial generic competition, while differentiated pediatric formulations can support better pricing.
• Controlled-substance quotas, security, and distribution requirements are material manufacturing and commercialization constraints.

Frequently Asked Questions

Can Methylin be reformulated without changing its FDA pathway?

Yes, some excipient changes can remain within an ANDA if the product remains pharmaceutically equivalent and bioequivalent. A materially different concentration, device, dosage form, or clinical use may require a 505(b)(2) application.

Is a sugar-free Methylin liquid likely to receive patent protection?

A sugar-free composition alone may be difficult to protect broadly. Patentability improves when the formulation includes a defined sweetener, buffer, preservative, and flavor system that produces unexpected stability, palatability, or dosing performance.

Does Methylin have biosimilar competition?

No. Methylin contains a small-molecule active ingredient, methylphenidate hydrochloride. Competition proceeds through generic-drug pathways rather than biosimilar approval under the Public Health Service Act.

Can a company patent a Methylin oral syringe?

A syringe alone generally offers limited product protection. A stronger strategy would claim an integrated product-and-device system that controls dosing, reduces measurement error, or is necessary for administration of a concentrated formulation.

What is the best first product for a Methylin follow-on program?

A conventional tablet offers the lowest technical and regulatory risk but also the weakest differentiation. A taste-masked chewable or sugar-free oral solution offers greater commercial upside, with higher formulation, stability, sensory, and regulatory risk.

References

1. DailyMed. (n.d.). Methylin methylphenidate hydrochloride tablet and chewable tablet labeling. U.S. National Library of Medicine.

2. DailyMed. (n.d.). Methylin methylphenidate hydrochloride oral solution labeling. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format. FDA.

5. U.S. Drug Enforcement Administration. (2024). Controlled substances regulations and methylphenidate scheduling. U.S. Department of Justice.